Sinary Biodistribution of chimeric mouse/human monoclonal antibody against non-specific cross-reacting antigen (chNCA Ab) was studied in athymic mice and patients with metastatic bone disease. 9=-rc-chNCA Ab showed a high labelling efficiency, stability and also a high binding ratio to human granulocytes. Since NCA showed cross-reactivity with carcinoembryonic antigen (CEA), animal experiments showed that 99"c-chNCA Ab was accumulated in the xenografted tumour which expressed CEA, suggesting the preserved immunoreactivity of labelled materials. In the clnical study, injected 99rc-chNCA Ab formed a high molcular weight complex immediately after intravenous aministration and was trapped mainly in liver. The first-phase plasma half-life was 6.4+ 1. Locher et al., 1986; CourtenayLuck et al., 1984). Production of the human anti-murine antibody (HAMA) is one of the most serious problems as far as murine MAbs are concerned. HAMA, produced in the sera of patients who received murine MAbs repeatedly, may result in the neutralisation of infused MAb or in allergic reactions (Schroff et al., 1985; Shawler et al., 1985) . Recent developments in genetic engineering enable us to use chimeric mouse-human MAbs which are expected to decrease the HAMA production, since chimeric MAbs consist of mouse variable regions and human constant regions (Boulianne et al., 1984) . However, there has been a report which describes the production of HAMA in serum samples of metastatic colorectal cancer patients after administration of chimeric MAb designated B72.3 (Khazaeli et al., 1991).
model; immunoscintigraphy
Radiolabelled monoclonal antibodies (MAbs) are used for the diagnosis and the therapy of cancer and some benign diseases (Mach et al., 1980; Locher et al., 1986; CourtenayLuck et al., 1984) . Production of the human anti-murine antibody (HAMA) is one of the most serious problems as far as murine MAbs are concerned. HAMA, produced in the sera of patients who received murine MAbs repeatedly, may result in the neutralisation of infused MAb or in allergic reactions (Schroff et al., 1985; Shawler et al., 1985) . Recent developments in genetic engineering enable us to use chimeric mouse-human MAbs which are expected to decrease the HAMA production, since chimeric MAbs consist of mouse variable regions and human constant regions (Boulianne et al., 1984) . However, there has been a report which describes the production of HAMA in serum samples of metastatic colorectal cancer patients after administration of chimeric MAb designated B72.3 (Khazaeli et al., 1991) .
Non-specific cross-reacting antigen (NCA) is expressed on the surface of human granulocytes and cross-reacts with carcinoembryonic antigen (CEA) (von Kleist et al., 1972) . Therefore, radiolabelled anti-NCA Ab has been successfully used for the diagnosis of infectious diseases and bone metastases of malignancies, although the distinction would not be made between sites of inflammation and sites of cancer expressing CEA (Locher et al., 1986; Reuland et al., 1991; Munz et al., 1990) .
In this study, chimenrc antibody against the NCA (chNCA Ab) was labelled with 9Tc pertechnetate, since 99'Tc was an ideal radionuclide for radioimmunodetection, and administered into tumour-beanng athymic mice and patients to compare the biodistribution. Patients with bone metastasis from prostate cancer were chosen for the clinical application, since prostate cancer often shows osteogenic metastasis, which could be imaged as a photopenic area on the immunoscintigraphy using radiolabelled anti-NCA Ab.
Materids and methods
Murine and chimeric mouse-human anti-NCA antibodies Murine anti-NCA Ab (mNCA Ab), IgG, isotype, was purified from ascites of Balb/c mouse inoculated intraperitoneally with hybridoma cells that were produced by the fusion of mouse myeloma cells and anti-NCA Ab-producing B-cells derived from Balb/c mouse immunised with CEA. Derived mNCA Ab reacted to NCA 50 and NCA 90. chNCA Ab was prepared by the method previously reported (Koga et al., 1990) . VY(VK) gene, isolated from hybridoma 2.7.1G.10., was linked to Cy(CK) gene from ARH77 human myeloma cell line. Recombinant DNA was sequentially transfected into p3x63-Ag8.653 mouse myeloma cell line by electroporation (Potter et al., 1984) . The transfectants were adapted to be grown in Iscove's modified Dulbecco's medium supplemented with bovine insulin (5 pg ml-'), human transferrin (10 pg ml-') and ethanolamine (1.53 pg ml-') and then cultured in a hollow fibre cell culture system (Cellmax 100, Cellco Advanced Bioreactors, Kensington, MD, USA). chNCA Ab was purified from the supernatant on SP-TOY OPEAL (Tosoh, Tokyo, Japan), QAE-TOY OPEAL (Tosoh), protein -A-Sepharose (Pharmacia, Uppsala, Sweden) and Sephacryl S-300 (Pharmacia) column.
MAb against human chorionic gonadotropin, IgG, was used as an irrelevant control Ab. Serum samples obtained from five patients who received 9'Tc-labelled murine MAb against CEA, designated BW431/126 (Baum et al., 1989) were used as control in the measurement of serum levels of HAMA and human anti-chimera antibody (HACA).
Radiolabelling procedure 'Tc labelling 9Tc labelling was performed according to -I bmisn of ddmmrc Ab in mnce and hIn N Oriuch et i phosphate-buffered saline (PBS), pH 7.5, were reduced by 4.8 pj of 97%, 2-mercaptoethanol (2-ME, Wako, Osaka, Japan) with 2-ME/MAb molar ratio of 10000:1 at 25°C for 30 min. The reduced antibodies were then purified by gel chromatography using G-25M Sephadex column (Pharmacia). The protein fraction was separated into 0.5 mg aliquots. For 99'Tc labelling, 50 p1 of hydroxymethylene diphosphonate (HMDP, Nihon Medi-physics, Nishinomiya, Japan) solution reconstituted with 5 ml of 0.9% sodium chloride was added to 0.5 mg of reduced antibody. Antibody-HMDP mixture was then incubated with 740 MBq of 99"Tc pertechnetate eluted from a 9Mo/9Tc generator (Dainabot, Tokyo, Japan) for 10 min. The labelling efficiency was determined by the cellulose acetate electrophoresis and quantitative measurement as reported previously (Watanabe et al., 1994) .
'"I labelling Radioiodination of both mNCA Ab and chNCA Ab was performed by the chloramine-T method (Hunter and Greenwood, 1962 Figure  3 ). Metastatic bone lesion could be seen as a photopenic area on 1 and 4 h posterior images (Figure 4 ). Blood clearance of HPLC analI sis show-ed that there A-as the first peak before the second peak of 'Tc-chNCA Ab under incubation condition similar to those pertaining to the clinical situation (5 ng of 9'9Tc-chNCA Ab with 20 MI serum). which indicated the evidence of a high molecular weight complex formation. However. there w-as apparently no complex formation when I x 10"-fold excess of 9Tc-chNCA Ab was incubated w-ith serum (5 jg of 9Tc-chNCA Ab with 20 ,l serum) as shou-n in Figure 7 .
No patient showed positive HACA or HAMA response in their sera within 19 weeks after injection of 9'9Tc-chNCA Ab.
whereas 60% of patients produced HAMA in their sera after injection of the same dose of 9Tc-BW431 26 (Figure 8 ). LoBuglio et al.. 1989 . HPLC analysis of plasma from the patient who received 9Tc-chNCA Ab revealed the formation of a high molecular weight complex in the circulation and there was no increment in free 9'Tc pertechnetate in the plasma detected by either whole body imaging or HPLC analysis. NCA has been found in various human tissues such as lung. spleen. granulocytes and also in the serum with a variety of molecular weights ranging from 50 to 160 kDa (von Kleist et al.. 1972; Bosslet et al.. 1985) . In vivo instability of reduction-mediated 'Tc-labelled Ab has been reported (Sakahara et al.. 1993) but no evidence of aggregation or complex formation was noted x-hen 'TcchNCA Ab was incubated With PBS (data not shown).
HPLC analysis of the diluted 'Tc-chNCA Ab incubated
With normal human serum in vitro demonstrated the same radioactivity peak corresponding to a high molecular %veight complex ( Figure 7) . Serum samples. which were absorbed by anti-NCA Ab and then incubated with 'Tc-chNCA Ab. showed only one peak which corresponded to 9'9Tc-chNCA Ab (data not shown). From these results. increased radioactivity in the liver is supposed to be caused by the complex formation of injected 'Tc-chNCA Ab with circulating NCA resulting in subsequent clearance by the reticuloendothelial system. Of note wxas the fact that a high molecular A-eight complex A-as only detected by HPLC under a certain incubation ratio of radiolabelled MAb to human serum. According to the recommendation of the Food and Drug Administration in USA (Center for Biologics Evaluation and Research. FDA 1993) . 'Tc-chNCA Ab was examined for binding to serum protein using HPLC by incubating 'TcchNCA Ab with human serum as a preclinical safety testing. though the high molecular weight complex was hardly demonstrable probably because of the saturation of antigen-bimding capacity present in the serum. On the contrary, when 'Tc-chNCA Ab and human serum were incubated under the strict dilution ratio (1 x 103-fold). which was the equivalent ratio of 'Tc-chNCA Ab to serum in the circulation. then a high molecular weight complex was clearly demonstrated by HPLC. The biodistribution proffle observed in this study was different from other studies. The disparity between the results of the biodistribution of '"'I-labelled MAb in man and mice has been reported (Ledermann et al.. 1993) . In the report. most of the radioactivitx was located in the bone marrow and spleen. since the radiolabelled MAb was bound to circulating granulocytes. Lack of immunodetection and complications associated With MAb cross-reactive with circulating cells had been reported (Diliman et al.. 1984 labelled MAb which formed a circulating immune complex have been reported (Hnatowich et al., 1987; Davidson et al., 1991) . In the present study, increased liver uptake of radiolabelled MAb was noted as in the previous studies, although the pharmacokinetics were different and imaging was not successful. Blood clearance of "Tc-chNCA Ab was much faster than in other studies and the mechanism of fast clearance and the liver accumulation of 9'9Tc-chNCA Ab remains to be clarified. None of the patients produced HAMA or HACA within 19 weeks after 99mTc-chNCA Ab injection, although three of five patients who received the same 1 mg of 99Tc-labelled murine Ab produced HAMA in their serum. There have been a few reports describing the immunogenicity of chimeric Abs.
Chimeric Abs designated 17-lA, L6 and NR-LU-13 had low immunogenicity, whereas '31I-labelled chimeric Ab, B72.3, had considerable immunogenicity LoBuglio et al., 1989; Meredith et al., 1991) . In the latter paper, seven of 12 patients with metastatic colon cancer had an antibody response after intravenous injection of 3.4 to 6.9 mg of chimeric B72.3, and a small portion of the antibody response was directed to epitopes requiring the presence of both murine V-region and human CH-1/Kc constant regions. These results may indicate that the inmunogenicity of chimeric Abs may depend on the amino acid sequences of murine V-region.
In conclusion, chNCA Ab was stably labelled with 'Tc pertechnetate and immunoreactivity was completely reserved with high-binding capacity to human granulocytes and CEAexpressing colon cancer cells. 99'c-chNCA Ab was safely administered to patients without generating HAMA or HACA response. In contrast to animal studies, however, circulating antigenic molecules reactive with chNCA Ab formed a high molecular weight complex immediately after the administration of 99mTc-chNCA Ab and were taken up in the liver. For safety HPLC analysis should be performed before clinical radioimmunodetection or radioimmunotherapy by incubating radiolabelled MAb with human serum under strict conditions.
